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ABSTRACT 
Objective: The objective of this research work was to develop a sensitive, precise, specific, linear and stability-indicating gradient HPLC method for 
the estimation of valsartan in bulk drug and in pharmaceutical preparations.  
Methods: Chromatographic separation was achieved on C-18 stationary phase with a gradient mobile phase consisting of orthophosphoric acid 
buffer (the pH of the solution was adjusted to 4.2±0.05 with triethylamine) and methanol. The eluent was monitored with PDA detector at 225 nm 
with a flow rate of 1.0 ml/min, run time of 65 min. 
Results: The method was linear over the range of 20-120μg/ml. The correlation coefficient was found to be 0.9994±0.02. In order to check the 
selectivity of the method for pharmaceutical preparations, forced degradation studies were carried out. Valsartan was found to be stable at light and 
oxidation experiments. The performance of the method was validated according to the present ICH guidelines for specificity, limit of detection, limit 
of quantification, linearity, accuracy, precision and robustness. .The LOQ was found to be 0.26µg/ml and the LOD was found to be 0.79µg/ml. 
Valsartan showed good correlation coefficient in the concentration range of 20-120μg/ml. The developed method was compared statistically by 
applying two-way anova and student's t-test to correlate with an isocratic method and was applied to bulk drug and tablet dosage form. There was 
no significant difference between the two methods. 
Conclusion: The proposed method was found to be accurate, precise, sensitive and robust. Hence, it can be used successfully for the routine 
analysis of valsartan in pharmaceutical formulation and for analysis of stability samples obtained during accelerated stability study. 
Keywords: RP-HPLC, Valsartan, Degradation products, Pharmaceutical dosage forms, Two-way ANOVA and student's t-test 




Valsartan (VAL) is chemically N-(1-Oxopentyl)-N-[2'-(1H-tetrazol-5-
yl) [1,1'-biphenyl]-4-yl] methyl]-L-valine.[1] It is a new potent, 
highly selective and orally active antihypertensive drug belonging to 
the family of Angiotensin II type I receptor antagonist. Angiotensin II 
receptor type I antagonists have widely used in the treatment of 
hypertension, heart failure, myocardial infarction and diabetic 
nephropathy.[2] Literature survey revealed that HPLC, LC-MS, protein 
precipitation, capillary electrophoresis and simultaneous UV-
spectrophotometric methods [3-15] are reported for estimation of 
VAL alone or on combination with other agents. As the published 
literature and knowledge of the molecule suggest, reversed phase 
liquid chromatography (RP-HPLC) is suitable for analysis of VAL. 
various methods are available for estimation of VAL in isocratic mode, 
but as the main aim was to resolve the compound from degraded 
products and impurities if any, the gradient method was chosen. 
 
 
Fig. 1: Chemical structure of Valsartan 
MATERIALS AND METHODS 
Chemicals and reagents 
A reference standard sample of VAL was obtained as a gift from 
Macleod’s Pharmaceuticals Ltd and commercial dosage form 
containing the studied drug were purchased from local market. 
HPLC grade methanol, orthophosphoric acid, triethylamine, and 
water were HPLC grade purchased from E. Merck, Mumbai, India. All 
the other chemicals and reagents used were of analytical grade and 
purchased from SD Fine Chemicals, Mumbai, India. 
Instrumentation and chromatographic system 
The chromatographic system consisted of a JASCO (Japan) 
chromatograph equipped with an LC–Net II/ADC, an MU–2010 plus 
PDA detector, a PU–2089 plus quaternary pump, an online degasser 
and a rheodyne model 7725 injector valve with 20 µl sample loop. 
The chromatograph is coupled with “Chrompass” software (version 
1.7.403.1).  
The chromatographic separations were performed at ambient 
temperature using Symmetry C18 column (4.6 mm×150 mm, 
particle size 5.0 µm). Separation was achieved using a gradient 
method. Mobile phase A comprised of orthophosphoric acid buffer 
(the pH of the solution was adjusted to 4.2±0.05 with triethylamine). 
Mobile phase B was methanol. orthophoshoric acid buffer (pH 4.2) 
was prepared by adding 5.5 ml of orthophosphoric acid in 1000 ml 
of HPLC grade water, adjusting the pH to 4.2±0.05 with 
triethylamine, diluting to 1000 ml with HPLC-grade water, and 
filtering through 0.45 m membrane filter. For the preparation of 
diluent, a mixture of buffer pH 4.2 and methanol (50:50v/v) filtered 
and degassed for 30 min prior to use. The eluent was monitored 
with PDA detector at 225 nm with a flow rate of 1.0 ml/min, run 
time of 65 min; sample size of 20 µl was carried out at room 
temperature all over the study. 
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Table 1: Gradient composition for analysis of VAL 
Time (min) Mobile phase A (% v/v) Mobile phase B (% v/v) Comment 
0→40 55 45 Isocratic 
40→55 55→20 45→80 Linear gradient 
55→57 20 80 Isocratic 
57→58 20→55 80→45 Linear gradient 
58→65 55 45 Re-equilibration 
 
Preparation of stock solution 
Stock solutions were prepared by accurately weighing 10 mg of VAL 
and transferring to 10 ml volumetric flasks containing 6 ml of 
methanol. The flasks were sonicated for 10 min to dissolve the 
solids. Volumes were made up to the mark with diluents, which gave 
1000μg/ml the drugs. Aliquots from the stock solutions were 
appropriately diluted with diluents to obtain working standards of 
100μg/ml of VAL. 
Calibration standards and quality control sample 
Different calibration standards ranging from 20, 40, 60, 80, 100 and 
120μg/ml were prepared by appropriate dilution of standard 
solution (1000μg/ml) with mobile phase. Three quality control 
samples at concentrations 60, 80 and 100μg/ml representing 50, 
100 and 150% respectively of assay concentration (40μg/ml) were 
prepared from the standard solution. An aliquot of 20μL of the 
solution was injected into HPLC system. 
Preparation of assay solution 
To determine the VAL content of tablet formulations, twenty 
tablets were weighed, to determine the average weight of the 
tablets, and then crushed and mixed using a mortar and pestle. A 
portion of powder equivalent to 1000μg/ml was accurately 
weighed into each of three 10 ml volumetric flasks and 5 ml 
methanol was added. Each solution was sonicated for 20 min to 
achieve complete dissolution of the VAL and the solutions were 
then diluted to volume with diluents, to yield concentrations of 
1000μg/ml, and filtered through a 0.22μm nylon membrane filter. 
The solution obtained was analyzed by HPLC.  
Forced degradation study 
Acidic degradation 
50 mg of VAL was accurately weighed and dissolved in 10 ml of 
methanol, then 5 ml of 0.1N HCl were added and kept at 80 °C about 
2 h in a water bath, the solution was allowed to attend ambient 
temperature then the solution was neutralized by 0.1N NaOH to pH 
7 and the volume made up to 50 ml with methanol. 
Alkali degradation 
50 mg of VAL was accurately weighed and dissolved in 10 ml of 
methanol, then 5 ml of 0.1N NaOH was added and kept at 80 °C 
about 2 h in a water bath. Then the solution was neutralized by 
0.1 N HCl to pH 7 and the volume made up to 50 ml with 
methanol.  
Oxidative degradation 
50 mg of VAL was accurately weighed and dissolved in 10 ml of 
methanol, then 5 ml of 10% H2O2 solution were added and kept at 80 
°C about 2 h in a water bath then volume was made up to 50 ml with 
methanol.  
Thermal degradation 
50 mg of VAL was spread in a borosilicate glass Petri dish and placed 
in a hot air oven maintained at 80 °C for 24 h, and then the solution 
was prepared to achieve a final concentration of 80μg/ml with 
methanol. 
Photodegradation 
50 mg of VAL was (covered with aluminum foil) and exposed in the 
UV chamber for 24 h; then the solution was prepared to achieve a 
final concentration of 80μg/ml with methanol.  
Method validation 
The method was validated according to International Conference on 
Harmonization [17] guidelines for validation of analytical 
procedures.  
RESULTS AND DISCUSSION  
HPLC method development and optimization  
Some important parameters, like pH of the mobile phase, 
concentration of buffer solution, percentage and type of organic 
modifiers (acetonitrile and methanol), different columns (CN 
column, C8 and C18), flow rates (0.5 to 2.0 ml/min) were attempted 
to resolve the good chromatographic separation of VAL. VAL and 
degraded products could not be separated without pH adjustment of 
the mobile phase. Various pH ranges (3 to 6) for mobile phase were 
tried, and the best resolution was obtained with pH 4.2.  
The method was optimized to provide a good separation of the 
components (acceptable theoretical plates and resolution between 
peaks) with a sufficient sensitivity and suitable peak symmetry 
(peak tailing factor<2). Symmetry C18 column (4.6 mm×150 mm, 
5.0 µm particles were preferred over the other columns. The mobile 
phase consisted of 55% phosphate buffer and 45% methanol to 80% 
buffer and 20% methanol within 40 min with a 1 ml/min flow rate. 
Retention times for VAL under these conditions were 27.04 (fig. 2). 
The quantitative analysis of the drug and its degradation products 
were performed at 225 nm. 
Gonzalez et al. [5] developed a HPLC method coupled to 
fluorescence detection using gradient elution mode and was applied 
to plasma samples obtained from hypertensive patients under 
clinical studies after oral administration of a therapeutic dose of 
some of these angiotensin II receptor antagonists. The objective of 
this research work reported was to develop a simple, precise, 
accurate gradient stability-indicating LC method for analysis of VAL 
in bulk and its formulations in the presence of degradation products 
and impurities.  
 
 





System suitability test is an integral part of method development 
and is used to ensure adequate performance of the chromatographic 
system. Retention time, a number of theoretical plates, asymmetrical 
factor, and peak area were evaluated for five replicate injections of 
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the drug at a concentration of 80μg/ml. The results given in table 2 
were within acceptable limits.  
 
Table 2: System suitability of HPLC method for VAL 
Parameters (Mean*±%RSD) 
Retention time 27.04±0.59 
No. of theoretical plates 9154.2±0.72 
Asymmetrical factor 1.05±0.47 
Peak area 7050360±0.68 
*Mean of five determinations 
 
Linearity 
VAL showed good correlation coefficient in the concentration range 
of 20-120μg/ml (fig. 3). Linearity was calculated by determining six 
standard working solutions containing VAL in triplicate (table 3). 
For the method, the linearity of calibration graph was validated by 
the high value of correlation of coefficient and the RSD for slope and 
intercept value was less than 2%.  
 
Table 3: Linear regression data for calibration curve of VAL 
Parameters VAL 
Linearity range(μg/ml) 20-120 
r *±RSD% 0.9994±0.02 
Slope*±RSD% 94265±0.26 
Intercept*±RSD%. 453560±1.60 
*Mean of three determinations 
 
Fig. 3: Calibration curve of valsartan in gradient mode 
 
Accuracy 
The accuracy of the method was checked by recovery study using 
standard addition method known the amount of standard VAL was 
added into the pre-analyzed sample and subjected it to the proposed 
high performance liquid chromatographic method.  
These studies were carried out at three levels i. e, (50, 100 and 150%). 
The recovery studies were carried out and the % recovery and 
standard deviation of the % recovery were calculated and presented in 
table 4.  
 
Table 4: Recovery study by standard addition method for VAL 
Sample Amount taken (μg/ml) Amount % Amount added  
(μg/ml) 




40 50 20 60 99.98±0.25 
40 100 40 80 99.90±0.35 
40 150 60 100 99.82±0.55 
 
Diavon-80 
40 50 20 60 100.21±0.47 
40 100 40 80 99.94±0.48 
40 150 60 100 100.26±0.45 
*Mean of five determinations 
 
Precision 
The precision of the method was determined by repeatability 
(intraday precision) and intermediate precision (inter-day 
precision) of VAL standard solutions. Repeatability was 
calculated by assaying three samples of each three different 
concentration levels on the same day. The inter-day precision 
was calculated by assaying three samples of each at three 
different concentration levels on three different days. The 
results are expressed as a relative standard deviation. The 
relative standard deviations were below 2%, which signifies the 
precision of both the methods (table 5). 
 
Table 5: Precision of the method 
Name of the formulation Intra-day precision (n =6) Inter-day precision (n = 6) 
Mean*(%)±RSD Mean*(%)±RSD 
Valzaar-80 99.97±0.35 99.91±0.72 
Diavon-80 100.11±0.33 100.13±0.61 
*Mean of three determinations injected six times at each concentration level 
 
Limits of detection (LOD) and quantification (LOQ) 
The LOQ and LOD were determined based on the 10 and 3.3 times 
the standard deviation of the response, respectively, divided by the 
slope of the calibration curve. The LOQ was found to be 0.26µg/ml, 
and the LOD was found to be 0.79µg/ml.  
Robustness 
In order to measure the extent of the method robustness, the most 
critical parameters were interchanged while keeping the other 
parameters unchanged, and in parallel, the chromatographic 
profile was observed and recorded. The chromatographic 
parameters were interchanged within the range of 1-10% of the 
optimum recommended conditions. The studied parameters were: 
mobile phase pH, flow rate, and detector wavelengths. The results 
indicated that the small change in the conditions did not 
significantly affect the determination of VAL. Under all 
deliberately varied conditions, the %RSD for the assay values 
(n=3) for VAL was found to be well within the acceptance limit of 
2%. The results are reported in table 6. 
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Table 6: Results from testing the robustness of the method 
Condition Modification Mean area* ±SD RSD Mean RT* 
(%) (min)±SD 
Mobile phase flow 
rate (mL/min) 
0.8 7078494±16792 0.23 29.95±0.05 
1 7062968±54957 0.77 27.08±0.04 
1.2 7097530±57017 0.8 26.95±0.15 
Mobile Phase pH 4 7033714±34615 0.49 27.04±0.10 
4.2 7070556±17718 0.25 27.08±0.04 
4.4 7074327±26629 0.37 27.05±0.08 
Detector wavelength (nm) 223 7072746±32695 0.46 26.94±0.06 
225 7067339±20404 0.28 26.94±0.11 
227 7077785±13108 0.18 27.13±0.10 
*Mean of three determinations 
 
Specificity and degradation studies 
When establishing the stability-indicating properties of analytical 
methods, the intermediate degradation products should not 
interfere with any stage of drug analysis. VAL was found to be stable 
at light and oxidation experiments. In acidic condition VAL degraded 
up to 9.2%, in basic condition up to 6.5% and in thermal condition 
12.2% degradation was observed for VAL. The results from forced 
degradation studies are given table 7.  
Chromatograms obtained from after degradation under different 
stress conditions are shown in–fig. 4, respectively. No peaks co-
eluted with the drug peak, suggesting the method enabled specific 
analysis of VAL in the presence of its degradation products. 
 
Table 7: Summary of forced degradation results of VAL 
Condition Time % Assay of active substance % Degradation 
Treated with 5 ml of 0.1 N HCl solution and kept at 80 °C on water bath 2 h 90.8 9.2 
Treated with 5 ml of 0.1 N NaOH solution and kept at 80 °C on water bath 2 h 93.5 6.5 
Treated with 5 ml of 10.0 % H2O2solution  
and kept at 80 °C on a water bath 
2 h 98.2 1.8 
Heated at 80 °C in oven 24 h 87.8 12.2 










Fig. 4: LC chromatograms of Valsartan (a) after acidic 
degradation (b) after basic degradation (c) after oxidative 
degradation (d) after thermal degradation (e) after 
photodegradation (f) formulation I (g) Formulation II 
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Use of the method for analysis of marketed formulations 
Two marketed samples have been analyzed to see the performance 
of the method. The first formulation taken was Valzaar-80 which 
contains 80 mg of VAL; the second formulation taken was Diavon-80 
contains 80 mg of VAL. Results obtained have been summarized in 
the table 8.  
 
Table 8: Results from assay of VAL in marketed formulation 
Formulation  Mean*±SD RSD (%) Recovery (%) 
Valzaar-80 80.04±0.33 0.41 100.05 
Diavon-80 79.93±0.28 0.35 99.91 
*Mean of six determinations 
Statistical comparison of gradient HPLC method and Isocratic HPLC 
To test the difference between the developed gradient liquid 
chromatographic method and our previous work isocratic HPLC 
method for estimation of VAL [16] statistical tests were performed 
for the level of confidence 95% (P = 0.05). Two-way ANOVA and 
One-way ANOVA was applied to test both methods–sample 
interaction and differences in method precision. Two-way ANOVA 
was used for comparison of two formulations by two 
chromatographic methods (table 9). One way ANOVA was used for 
comparison of each formulation by chromatographic methods (table 
9). To test means between different chromatographic methods 
paired student’s t–test was applied. The test removes any variation 
between samples. For VAL, the two formulations were compared for 
the chromatographic methods (table 10). 
 
Table 9: Comparison of chromatographic methods between valzaar-80 and diavon-80 
ANOVA-Two Way with replication 
Source of Variation SS df MS F stat P-value F crit 
Sample 0.0082 1 0.0082 0.0868 0.7713 4.3512 
Columns 0.0031 1 0.0031 0.0331 0.8573 4.3512 
Interaction 0.0455 1 0.0455 0.4786 0.4969 4.3512 
Within 1.9010 20 0.0950    
Fstat<Fcrit 
ANOVA: Single Factor (VALZAAR-80) 
Source of Variation SS df MS F stat P-value F crit 
Between Groups 0.0363 1 0.0363 0.3221 0.5828 4.9646 
Within Groups 1.1269 10 0.1126    
Fstat<Fcrit 
ANOVA: Single Factor(DIAVON-80) 
Source of Variation SS df MS F stat P-value F crit 
Between Groups 0.0123 1 0.0123 0.1595 0.6979 4.9646 
Within Groups 0.7741 10 0.0774    
Fstat<Fcrit 
 
Table 10: Student’s t–test for different chromatographic methods 
t-Test: paired two sample for means 
Parameters Valzaar-80 Diavon-80 
Pearson correlation -0.5097 -0.4082 
t Stat  0.5053 0.3460 
t Critical two-tail = 2.5705 t stat<t crit t stat<t crit 
 
CONCLUSION 
A gradient stability-indicating reversed phase high performance 
liquid chromatographic method for valsartan in bulk and 
pharmaceutical dosage form was undertaken in the present research 
work. The method was found to be specific, as there was no 
interference of any co-eluting impurities after stress degradation 
study. The method was validated according to ICH guidelines and 
correlated by statistical analysis. The proposed method is found to 
be accurate, precise, sensitive and robust. Hence, it can be used 
successfully for the routine analysis of valsartan in pharmaceutical 
formulation and for analysis of stability samples obtained during 
accelerated stability study. 
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